Wedbush lowered the firm’s price target on Larimar Therapeutics (LRMR) to $15 from $17 and keeps an Outperform rating on the shares. Larimar management received additional FDA feedback on its nomlabofusp regulatory filing requirements which includes specificity on the size of the required safety database, and while the clarity is positive, this will extend the filing timeline to 2Q26 from year-end 2025, the analyst tells investors in a research note. The firm is moving out its launch timing for nomlabofusp in the U.S. by about one quarter as the prior estimates assumed initial launch in 1Q27, and says that while the delay is “disappointing,” this is offset by clarity on the regulatory package.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LRMR:
- Larimar Therapeutics selloff a buying opportunity, says Citi
- Larimar Therapeutics Updates on Nomlabofusp Progress
- Larimar Therapeutics: FDA Guidance Boosts Buy Rating Amid Promising Regulatory Progress
- Larimar Therapeutics Receives FDA Guidance for BLA Submission
- Larimar announces FDA safety database recommendations for nomlabofusp BLA